Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16457459 | 0.83 | ALDH1A1 (0.32) | MAPTRAB9AALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL28796325 | 0.82 | FFAR1 (0.38) | LMNAMAPTTSHRALDH1A1KMT2A | |
| SCHEMBL1662205 | 0.81 | MAPT (0.37) | L3MBTL1LMNAMAPTRAB9ATSHR | |
| SCHEMBL15391066 | 0.81 | MAPT (0.37) | L3MBTL1LMNAMAPTRAB9ATSHR | |
| SCHEMBL1662668 | 0.76 | MAPK1 (0.33) | L3MBTL1LMNAMAPTRAB9ATSHR | |
| SCHEMBL11838560 | 0.72 | LMNA (0.38) | L3MBTL1LMNAMAPTTSHRALDH1A1 | |
| SCHEMBL16475601 | 0.72 | PTGS2 (0.32) | LMNAMAPTRAB9AALDH1A1KMT2A | |
| SCHEMBL22307574 | 0.70 | TSHR (0.41) | L3MBTL1LMNAMAPTTSHRALDH1A1 | |
| SCHEMBL2062770 | 0.69 | ALDH1A1 (0.42) | L3MBTL1LMNAMAPTRAB9AALDH1A1 | |
| SCHEMBL11832514 | 0.69 | L3MBTL1 (0.40) | L3MBTL1LMNATSHRALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102574852-B | AKT inhibitors | LILLY CO ELI | 2014-06-25 | — | — | CN | disclosed |
| EP-2491032-B1 | AKT INHIBITORS | LILLY CO ELI (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8436002-B2 | AKT inhibitors | ELI LILLY AND COMPANY (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2491032-A1 | AKT INHIBITORS | Eli Lilly and Company (US) | 2012-08-29 | — | — | EP | disclosed |
| CN-102574852-A | AKT inhibitors | LILLY CO ELI | 2012-07-11 | — | — | CN | disclosed |
| US-20120149684-A1 | AKT INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011050016-A1 | AKT INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149684-A1 | AKT INHIBITORS | AKT2, PIK3CA, AKT3 | L3MBTL1 4845/4885LMNA 4267/4885MAPT 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.